Home › Companies › KEROS THERAPEUTICS INC. › 2024-2025
Compiled from SEC Form N-PX filings and KEROS THERAPEUTICS INC.’s Form 8-K, filed 2025-06-09 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore KEROS THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are KEROS THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-09 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Mary Ann Gray, Ph.D. | 13,703,361 | -- | -- | 10,006,911 | 4,297,008 | Majority: yes |
| Elect Director: Ran Nussbaum | 22,703,180 | -- | -- | 5,304,100 | 4,297,008 | Majority: yes |
| Elect Director: Alpna Seth, Ph.D. | 15,091,438 | -- | -- | 8,618,834 | 4,297,008 | Majority: yes |
| Proposal 2: Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2025 The Company's stockholders appr | 26,436,418 | 217,655 | 855,774 | -- | -- | Majority: yes |
| Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3 | 18,580,618 | 4,166,083 | 963,571 | -- | 4,297,008 | Majority: yes |
Source: KEROS THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-09 — read the filing on EDGAR.
Each item below shows how the 153 asset managers that disclosed a KEROS THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of KEROS THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 5 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
KEROS THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3”): 18,580,618 for, 4,166,083 against, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 40,562,047 outstanding shares: 45.8% for, 10% against (56% of the company cast a for/against vote).
The 145 asset managers below cast 80% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,571,139 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 0 | 2,512,823 | 0 | 0 | Against |
| BlackRock | 2,382,391 | 0 | 0 | 0 | For |
| Federated Hermes | 2,353,114 | 0 | 0 | 0 | For |
| Logos Global Management LP | 0 | 2,000,000 | 0 | 0 | Against |
| State Street | 1,906,309 | 0 | 0 | 0 | For |
| Fidelity | 1,590,933 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 1,357,370 | 0 | 0 | 0 | For |
| DE Shaw | 1,112,605 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 1,018,734 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 806,375 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 552,506 | 0 | 0 | 0 | For |
| Charles Schwab | 483,692 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 419,586 | 0 | 0 | 0 | For |
| ALKEON CAPITAL MANAGEMENT LLC | 258,152 | 0 | 0 | 0 | For |
| Northern Trust | 239,401 | 0 | 0 | 0 | For |
| Point72 | 190,297 | 0 | 0 | 0 | For |
| TFG Asset Management GP Ltd | 183,000 | 0 | 0 | 0 | For |
| Western Standard LLC | 158,433 | 0 | 0 | 0 | For |
| Clearbridge Investments, LLC | 143,914 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 130,316 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 121,556 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 120,198 | 0 | 0 | 0 | For |
| Stonepine Capital Management, LLC | 111,900 | 0 | 0 | 0 | For |
| Legg Mason | 111,700 | 0 | 0 | 0 | For |
Showing the 25 largest of 145 asset managers. See all 145 in the interactive database.
Combines 2 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
KEROS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Alpna Seth, Ph.D.”): 15,091,438 for, 8,618,834 withheld, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 40,562,047 outstanding shares: 37% for, 21% withheld (58% of the company cast a for/withheld vote).
The 48 asset managers below cast 100% of the shares they voted on this item FOR (6,891,649 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,522,533 | 0 | 0 | 0 | For |
| BlackRock | 1,173,721 | 0 | 0 | 0 | For |
| Federated Hermes | 1,165,882 | 0 | 0 | 0 | For |
| Fidelity | 715,367 | 0 | 433,653 | 0 | For |
| State Street | 665,314 | 0 | 1,552 | 0 | For |
| ACAP Strategic Fund | 0 | 0 | 419,586 | 0 | Abstain |
| Charles Schwab | 241,835 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 120,198 | 0 | Abstain |
| Legg Mason | 111,700 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 83,163 | 0 | Abstain |
| Equitable | 52,247 | 0 | 28,510 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 50,844 | 0 | 0 | 0 | For |
| Lincoln Financial | 24,800 | 0 | 20,481 | 0 | For |
| Guardian Variable Products Trust | 26,000 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 24,500 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 22,978 | 0 | Abstain |
| Goldman Sachs | 21,361 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 19,481 | 0 | Abstain |
| Global X | 19,447 | 0 | 0 | 0 | For |
| Northern Trust | 17,832 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 16,212 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 12,693 | 0 | Abstain |
| T. Rowe Price | 0 | 0 | 12,145 | 0 | Abstain |
| John Hancock | 0 | 0 | 11,429 | 0 | Abstain |
| JPMorgan | 9,589 | 0 | 0 | 0 | For |
Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.
Combines 2 wordings of this item as funds reported it.
58% Majority: yes · of votes cast
KEROS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mary Ann Gray, Ph.D.”): 13,703,361 for, 10,006,911 withheld, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 40,562,047 outstanding shares: 34% for, 25% withheld (58% of the company cast a for/withheld vote).
The 48 asset managers below cast 100% of the shares they voted on this item FOR (6,891,649 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,522,533 | 0 | 0 | 0 | For |
| BlackRock | 1,173,721 | 0 | 0 | 0 | For |
| Federated Hermes | 1,165,882 | 0 | 0 | 0 | For |
| Fidelity | 715,367 | 0 | 433,653 | 0 | For |
| State Street | 665,314 | 0 | 1,552 | 0 | For |
| ACAP Strategic Fund | 0 | 0 | 419,586 | 0 | Abstain |
| Charles Schwab | 241,835 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 120,198 | 0 | Abstain |
| Legg Mason | 111,700 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 83,163 | 0 | Abstain |
| Equitable | 52,247 | 0 | 28,510 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 50,844 | 0 | 0 | 0 | For |
| Lincoln Financial | 24,800 | 0 | 20,481 | 0 | For |
| Guardian Variable Products Trust | 26,000 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 24,500 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 22,978 | 0 | Abstain |
| Goldman Sachs | 21,361 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 19,481 | 0 | Abstain |
| Global X | 19,447 | 0 | 0 | 0 | For |
| Northern Trust | 17,832 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 16,212 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 12,693 | 0 | Abstain |
| T. Rowe Price | 0 | 0 | 12,145 | 0 | Abstain |
| John Hancock | 0 | 0 | 11,429 | 0 | Abstain |
| JPMorgan | 9,589 | 0 | 0 | 0 | For |
Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.
Combines 2 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
KEROS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ran Nussbaum”): 22,703,180 for, 5,304,100 withheld, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 40,562,047 outstanding shares: 56% for, 13% withheld (69% of the company cast a for/withheld vote).
The 48 asset managers below cast 100% of the shares they voted on this item FOR (6,874,603 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,522,533 | 0 | 0 | 0 | For |
| BlackRock | 1,173,721 | 0 | 0 | 0 | For |
| Federated Hermes | 1,165,882 | 0 | 0 | 0 | For |
| Fidelity | 715,367 | 0 | 433,653 | 0 | For |
| State Street | 666,100 | 0 | 766 | 0 | For |
| ACAP Strategic Fund | 0 | 0 | 419,586 | 0 | Abstain |
| Charles Schwab | 241,835 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 120,198 | 0 | Abstain |
| Legg Mason | 111,700 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 83,163 | 0 | Abstain |
| Equitable | 52,247 | 0 | 28,510 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 50,844 | 0 | 0 | 0 | For |
| Lincoln Financial | 24,800 | 0 | 20,481 | 0 | For |
| Guardian Variable Products Trust | 26,000 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 24,500 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 22,978 | 0 | Abstain |
| Goldman Sachs | 21,361 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 19,481 | 0 | Abstain |
| Global X | 19,447 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 17,832 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 16,212 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 12,693 | 0 | Abstain |
| T. Rowe Price | 0 | 0 | 12,145 | 0 | Abstain |
| John Hancock | 0 | 0 | 11,429 | 0 | Abstain |
| JPMorgan | 9,589 | 0 | 0 | 0 | For |
Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.
99.1% Majority: yes · of votes cast
KEROS THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December ”): 26,436,418 for, 217,655 against, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 40,562,047 outstanding shares: 65% for, 0.6% against (66% of the company cast a for/against vote).
The 48 asset managers below cast 100% of the shares they voted on this item FOR (8,125,506 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,522,533 | 0 | 0 | 0 | For |
| BlackRock | 1,173,721 | 0 | 0 | 0 | For |
| Federated Hermes | 1,165,882 | 0 | 0 | 0 | For |
| Fidelity | 1,149,020 | 0 | 0 | 0 | For |
| State Street | 666,866 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 419,586 | 0 | 0 | 0 | For |
| Charles Schwab | 241,835 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 120,198 | 0 | 0 | 0 | For |
| Legg Mason | 111,700 | 0 | 0 | 0 | For |
| TIAA | 83,163 | 0 | 0 | 0 | For |
| Equitable | 80,757 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 50,844 | 0 | 0 | 0 | For |
| Lincoln Financial | 45,281 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 26,000 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 24,500 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 22,978 | 0 | 0 | 0 | For |
| Goldman Sachs | 21,361 | 0 | 0 | 0 | For |
| ProShares | 19,481 | 0 | 0 | 0 | For |
| Global X | 19,447 | 0 | 0 | 0 | For |
| Northern Trust | 17,832 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 16,212 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 12,693 | 0 | 0 | 0 | For |
| T. Rowe Price | 12,145 | 0 | 0 | 0 | For |
| John Hancock | 11,429 | 0 | 0 | 0 | For |
| JPMorgan | 9,589 | 0 | 0 | 0 | For |
Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.
Combines 4 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
KEROS THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3”): 18,580,618 for, 4,166,083 against, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 40,562,047 outstanding shares: 45.8% for, 10% against (56% of the company cast a for/against vote).
The 4 asset managers below cast 17% of the shares they voted on this item FOR (187,500 for, 928,657 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0 | 928,623 | 0 | 0 | Against |
| EcoR1 Capital, LLC | 187,500 | 0 | 0 | 0 | For |
| GAMMA Investing LLC | 0 | 34 | 0 | 0 | Against |
| Ikarian Capital, LLC | 0 | 0 | 0 | 0 | -- |
82% Majority: yes · of votes cast
KEROS THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3”): 18,580,618 for, 4,166,083 against, per its Form 8-K filed 2025-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 40,562,047 outstanding shares: 45.8% for, 10% against (56% of the company cast a for/against vote).
The 4 asset managers below cast 51.0% of the shares they voted on this item FOR (27,572 for, 26,505 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ALGERT GLOBAL LLC | 27,480 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 26,505 | 0 | 0 | Against |
| Coyle Financial Counsel LLC | 46 | 0 | 0 | 0 | For |
| SIERRA SUMMIT ADVISORS LLC | 46 | 0 | 0 | 0 | For |
Ranked by the number of KEROS THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 40,562,047 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 6.34% |
| 2 | ADAR1 Capital Management, LLC | 6.20% |
| 3 | BlackRock | 5.87% |
| 4 | Federated Hermes | 5.80% |
| 5 | Logos Global Management LP | 4.93% |
| 6 | State Street | 4.70% |
| 7 | Fidelity | 3.92% |
| 8 | Nantahala Capital Management, LLC | 3.35% |
| 9 | DE Shaw | 2.74% |
| 10 | ORBIMED ADVISORS LLC | 2.51% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with ADAR1 | 13.29% | DEF14A |
| Ran Nussbaum | 11.89% | DEF14A |
| Tomer Kariv | 11.89% | DEF14A |
| Entities affiliated with Pontifax | 11.80% | DEF14A |
| BlackRock | 6.87% | 13F |
| Madison Avenue Partners, LP | 6.45% | 13G |
| JPMorgan Chase | 6.41% | 13F |
| Vanguard Group | 6.33% | 13F |
| Jasbir Seehra, Ph.D. | 4.24% | DEF14A |
| Morgan Stanley | 4.19% | 13F |
Percentages above are of 40,562,047 shares outstanding, as reported by KEROS THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from KEROS THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At KEROS THERAPEUTICS INC.'s shareholder meeting held 2025-06-04, in the 2024-2025 proxy season, 153 asset managers reported how they voted in their SEC Form N-PX filings, covering 837 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers as… — FOR was 82% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: KEROS THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-09.
KEROS THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.